Overview

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a blinded, placebo controlled, cross-over trial evaluating the safety of two dose-levels of ARD-501 in subjects with ASD.
Phase:
Phase 2
Details
Lead Sponsor:
Aardvark Therapeutics, Inc.
Collaborator:
Center for Psychiatry And Behavioral Medicine Inc.